November 14th 2024
Your daily dose of the clinical news you may have missed.
Early-Onset of Type 2 Diabetes Linked to Early Death
July 25th 2006PHOENIX, Ariz. -- The onset of type 2 diabetes before age 20 in Pima Indians, who are genetically prone to the disease, was associated with an increased risk of early kidney failure and death between ages 25 to 55, researchers reported.
Lifestyle Can Fend off Type 2 Diabetes Genetic Risk
July 20th 2006BOSTON -- Two common genetic variants appear to contribute to the development of type 2 diabetes for some patients with impaired glucose tolerance, found researchers here. But lifestyle moves seem to be able to combat the enhanced risk.
ADA: Investigational Type 2 Diabetes Drug Lowers Weight and Improves Insulin Function
June 13th 2006WASHINGTON - Liraglutide, an investigational injectable drug for type 2 diabetes, has produced significant decreases in HbA1c levels, as well as significant and sustained weight loss, according to phase 2 studies.
ADA: Investigational Januvia Put Through Its Paces for Diabetes
June 11th 2006WASHINGTON ? Januvia (sitagliptin), an investigational oral agent for type 2 diabetes, appears to be effective when given as a monotherapy or as an adjunct to Glucophage (metformin) or Actos (pioglitazone), reported researchers here.
The Diabetes Epidemic:Keys to Prevention, Guide to Therapy
May 1st 2006Diabetes is epidemic! The numbersare truly alarming. In 1997, official datashowed that 16 million people in theUnited States had diabetes. Approximately1 million had type 1 disease,and 10.4 million had type 2 disease; theremainder had undiagnosed diabetes.1If these numbers are projected outagainst an annual increase in diseaseprevalence of about 3.5%, it means thatby the year 2028, 50 million people willhave diabetes. However, the actual rateis closer to 7% each year. As such, approximately100 million Americans-roughly 1 of every 4-will have diabetesby 2028.
Antihypertensives and Diabetes: Is There a Connection?
January 1st 2006The prevalence of type 2 diabetes is expected to continue to increase rapidly, and it is not surprising that the issue of the potential effects of different classes of antihypertensive drugs on glucose metabolism and glycemic control has sparked debate.